Although previous studies have shown that AP4 could play a positive (Liu et al., 2012) or negative role (Buechler, 2009) in chemotherapy sensitivity in different carcinomas, we have shown that AP4 depresses the chemotherapy sensitivity of HCC via LAPTM4B in this research. This evidence concerns the gene TFAP4 and hepatocellular carcinoma.